BACKGROUND: Platelet glycoprotein (GP) IIb/IIIa receptor blockade improves clinical outcomes in percutaneous coronary interventions and in @entity1187 . @entity882 is a serious complication well described with the use of the prototype @entity1427 /IIIa inhibitor abciximab. Its association with other agents of this class has been underemphasized. OBJECTIVES: To determine the incidence of @entity882 in a cohort of @entity1 treated with eptifibatide at a tertiary cardiac centre. @entity1 AND METHODS: Chart review of consecutive @entity1 treated with eptifibatide at the study institution. RESULTS: There were four (1.3%) cases of acute @entity882 (platelet count less than 100 x 10(9)/L) among 305 @entity1 reviewed. One @entity1 had been previously exposed to eptifibatide. The other three @entity1 are described. In each case, platelet counts declined within 6 h of receiving eptifibatide. Recovery of platelet counts was noted within 6 to 30 h after withdrawal of eptifibatide. No @entity1 suffered an adverse clinical event related to @entity882 . CONCLUSIONS: It is important to monitor platelet counts closely after initiation of @entity1427 /IIIa inhibitor therapy, not only for abciximab, but also for small molecule inhibitors such as eptifibatide. Monitoring of platelet counts at 2 to 6 h and 24 h will detect most cases of acute @entity882 . Adverse events may be prevented by prompt discontinuation of @entity1427 /IIIa inhibitor therapy.

Acute XXXX associated with eptifibatide therapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndromes'] @entity1427 :: ('3674', 'Gene') :: ['GPIIb'] @entity882 :: ('MESH:D013921', 'Disease') :: ['Thrombocytopenia', 'thrombocytopenia']
@entity882 :: (MESH:D013921,Disease) :: ['thrombocytopenia']
